Coagulation Failure in Patients With Acute‐on‐Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio

Annabel Blasi, Andrea Calvo, Verónica Prado, Enric Reverter, Juan Carlos Reverter, María Hernández‐Tejero, Fátima Aziz, Alex Amoros, Andres Cardenas, Javier Fernández – 23 May 2018 – Balanced hemostasis with hypocoagulable and hypercoagulable features may occur in acute‐on‐chronic liver failure (ACLF). The characteristics and prognostic impact of the coagulation profile in ACLF are unknown. Consecutive patients with ACLF (n = 36) and acute decompensation (AD; n = 24) were included. Blood samples for thromboelastometry (TE) were obtained at admission and 72 hours thereafter.

Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma

Mariya L. Samoylova, Neil Mehta, John P. Roberts, Francis Y. Yao – 21 May 2018 – Current guidelines recommend ultrasound (US) for hepatocellular carcinoma (HCC) surveillance in cirrhosis. We assess predictors of decreased US sensitivity for detecting HCC. At a single center in the United States, all HCC patients evaluated for liver transplantation (LT) received an abdominal US. From 2007‐2015, consecutive patients presenting for untreated lesions found on computed tomography (CT) or magnetic resonance imaging (MRI) within 3 months of US were compared with US findings.

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

Derek J. Erstad, Christian T. Farrar, Sarani Ghoshal, Ricard Masia, Diego S. Ferreira, Yin‐Ching Iris Chen, Ji‐Kyung Choi, Lan Wei, Phillip A. Waghorn, Nicholas J. Rotile, Chuantao Tu, Katherine A. Graham‐O'Regan, Mozhdeh Sojoodi, Shen Li, Yang Li, Guogiang Wang, Kathleen E. Corey, Yat Sun Or, Lijuan Jiang, Kenneth K. Tanabe, Peter Caravan, Bryan C. Fuchs – 21 May 2018 – We examined a novel farnesoid X receptor agonist, EDP‐305, for its antifibrotic effect in bile duct ligation (BDL) and choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) models of hepatic injury.

MicroRNA‐26‐5p functions as a new inhibitor of hepatoblastoma by repressing lin‐28 homolog B and aurora kinase a expression

Yutong Zhang, Yulan Zhao, Jianguo Wu, Suthat Liangpunsakul, Junqi Niu, Li Wang – 21 May 2018 – Hepatoblastoma (HB) is the most common liver tumor in children. Despite recent improvements in treatment strategies, the survival of children with hepatoblastoma remains poor. In this study, we identified a novel role of microRNA‐26a‐5p (miR‐26a‐5p), lin‐28 homolog B (LIN28B), Ras‐related nuclear protein (RAN), and aurora kinase A (AURKA) in HB. The expression of LIN28B, RAN, and AURKA was significantly up‐regulated in human HB livers and cell lines.

Subscribe to